Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | VDR | P11473 | 1/20 | 0.39 |
| ▸ | JUN | P05412 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24328600 | 1.00 | FDPS (0.43) | FDPSALDH1A1SMN1; SMN2KDM4EGLA | |
| SCHEMBL24328789 | 1.00 | FDPS (0.43) | FDPSALDH1A1SMN1; SMN2KDM4EGLA | |
| SCHEMBL29628230 | 0.86 | FDPS (0.49) | FDPSALDH1A1SMN1; SMN2KDM4EGLA | |
| SCHEMBL1545332 | 0.84 | FDPS (0.63) | FDPSALDH1A1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL6980381 | 0.83 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KDM4EGLAVDR | |
| SCHEMBL20612384 | 0.82 | CFD (0.43) | ALDH1A1SMN1; SMN2KDM4EGLAVDR | |
| SCHEMBL26750481 | 0.81 | ALDH1A1 (0.55) | FDPSALDH1A1SMN1; SMN2GLAVDR | |
| SCHEMBL26750471 | 0.81 | ALDH1A1 (0.55) | FDPSALDH1A1SMN1; SMN2GLAVDR | |
| SCHEMBL11595224 | 0.81 | ALDH1A1 (0.55) | FDPSALDH1A1SMN1; SMN2GLAVDR | |
| SCHEMBL1042328 | 0.81 | PTPN1 (0.49) | ALDH1A1SMN1; SMN2KDM4EGLAVDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145634-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-05-08 | — | — | US | disclosed |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| CN-115215808-A | Compositions and methods for treating cancer | 加利福尼亚大学董事会 | 2022-10-21 | — | — | CN | disclosed |
| US-11377451-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2022061202-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| CN-113811528-A | Compositions and methods for treating cancer | 加利福尼亚大学董事会 | 2021-12-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145634-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | FDPS 2954/4885ALDH1A1 2784/4885SMN1; SMN2 2727/4885 |
| US-11377451-B2 | Compositions and methods for treating cancer | TP53, EGFR, SLC2A1 | FDPS 3120/4885ALDH1A1 2649/4885SMN1; SMN2 2616/4885 |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | FDPS 2905/4885ALDH1A1 2584/4885SMN1; SMN2 2721/4885 |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | FDPS 2954/4885ALDH1A1 2784/4885SMN1; SMN2 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.